Custo-efetividade do uso do dispositivo de by-pass trabecular (iStent® Trabecular Micro- Bypass) associado a cirurgia de catarata para o tratamento conjunto do glaucoma primário de ângulo aberto e da catarata sob a perspectiva do Sistema de Saúde Suplementar no Brasil.
Saved in:
| Title: | Custo-efetividade do uso do dispositivo de by-pass trabecular (iStent® Trabecular Micro- Bypass) associado a cirurgia de catarata para o tratamento conjunto do glaucoma primário de ângulo aberto e da catarata sob a perspectiva do Sistema de Saúde Suplementar no Brasil. |
|---|---|
| Alternate Title: | Cost-effectiveness of using the trabecular by-pass device (iStent® Trabecular Micro-Bypass) combined with cataract surgery for the treatment of primary open-angle glaucoma and cataract from the Supplementary Health System perspective in Brazil. |
| Authors: | Paletta Guedes, Ricardo Augusto1,2,3 palettaguedes@yahoo.com, Pepe, Camila4, Teich, Vanessa5, Marcelo Gravina, Daniela1,2, Paletta Guedes, Vanessa Maria1,2, Chaoubah, Alfredo2 |
| Source: | JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde. Aug2020, Vol. 12 Issue 2, p109-120. 12p. |
| Subjects: | ECONOMIC aspects of diseases, OPEN-angle glaucoma, CATARACT surgery, EYE drops, BRAZILIANS |
| Geographic Terms: | BRAZIL |
| Abstract (English): | Objective: To evaluate whether the incorporation of the iStent® Trabecular Micro-Bypass implant is cost-effective for the treatment of primary open-angle glaucoma (POAG) in patients undergoing cataract surgery from the perspective of the supplementary healthcare system in Brazil. Methods: An analytical Markov model was developed and costs were obtained from the Brazilian supplementary health perspective (direct medical costs). Effectiveness was measured in "progression free life years (PFLY)". The time horizon was the average life expectancy of the Brazilian population. Data were obtained through review and critical analysis of the literature. The base case was: glaucomatous patients with cataract who underwent isolated cataract surgery and continued use of antiglaucomatous eye drops. We tested whether incorporating iStent® Trabecular Micro-Bypass in this scenario would be cost effective. The outcome measure was the incremental cost-effectiveness ratio (ICER: R$/PFLY). We performed univariate and probabilistic sensitivity analyses to test the robustness of the model. Results: Incorporating the iStent® Trabecular Micro-Bypass increases initial costs but improves disease control, making glaucoma stable longer and reducing future costs due to disease progression. The ICER was R$ 5,491.99/PFLY. The model was robust in sensitivity analyses. Conclusion: This analysis suggests that the incorporation of the iStent® Trabecular Micro-Bypass combined with cataract surgery would be cost-effective for joint cataract and POAG treatment in the supplementary health setting in Brazil. [ABSTRACT FROM AUTHOR] |
| Abstract (Portuguese): | Objetivo: Avaliar se a incorporação do implante trabecular iStent® Trabecular Micro-Bypass é custo- -efetiva para o tratamento do glaucoma primário de ângulo aberto (GPAA) em pacientes que serão submetidos a cirurgia de catarata sob a perspectiva do Sistema de Saúde Suplementar no Brasil. Métodos: Foi elaborado um modelo analítico de Markov, cujos custos foram obtidos a partir da perspectiva da saúde suplementar brasileira (custos médicos diretos). A efetividade foi medida em "anos de vida livres de progressão (PFLY)". O horizonte temporal foi a expectativa de vida média da população brasileira. Os dados foram obtidos por meio da revisão e da análise crítica da literatura. O caso base foi: portadores de GPAA e catarata submetidos a cirurgia de catarata isolada e manutenção do uso de colírios antiglaucomatosos. Testou-se se a incorporação do iStent® Trabecular Micro- Bypass nesse cenário seria custo-efetiva. A medida de desfecho foi a razão de custo-efetividade incremental (RCEI: R$/PFLY). Realizou-se análise de sensibilidade univariada e probabilística para testar a robustez do modelo. Resultados: A incorporação do iStent® Trabecular Micro-Bypass gera um aumento dos custos inicialmente, mas melhora o controle da doença, tornando o glaucoma estável por mais tempo e diminuindo os custos futuros relacionados à progressão da doença. A RCEI foi de R$ 5.491,99/PFLY. O modelo mostrou-se robusto nas análises de sensibilidade. Conclusão: Esta análise sugere que a incorporação do implante iStent® Trabecular Micro-Bypass combinado com a cirurgia de catarata seria custo-efetiva para o tratamento conjunto da catarata e do GPAA no cenário da saúde suplementar no Brasil. [ABSTRACT FROM AUTHOR] |
| Copyright of JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde is the property of JBES: Brazilian Journal of Health Economics and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 145621031 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Custo-efetividade do uso do dispositivo de by-pass trabecular (iStent® Trabecular Micro- Bypass) associado a cirurgia de catarata para o tratamento conjunto do glaucoma primário de ângulo aberto e da catarata sob a perspectiva do Sistema de Saúde Suplementar no Brasil. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Cost-effectiveness of using the trabecular by-pass device (iStent® Trabecular Micro-Bypass) combined with cataract surgery for the treatment of primary open-angle glaucoma and cataract from the Supplementary Health System perspective in Brazil. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Paletta+Guedes%2C+Ricardo+Augusto%22">Paletta Guedes, Ricardo Augusto</searchLink><relatesTo>1,2,3</relatesTo><i> palettaguedes@yahoo.com</i><br /><searchLink fieldCode="AR" term="%22Pepe%2C+Camila%22">Pepe, Camila</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Teich%2C+Vanessa%22">Teich, Vanessa</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Marcelo+Gravina%2C+Daniela%22">Marcelo Gravina, Daniela</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Paletta+Guedes%2C+Vanessa+Maria%22">Paletta Guedes, Vanessa Maria</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Chaoubah%2C+Alfredo%22">Chaoubah, Alfredo</searchLink><relatesTo>2</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22JBES%3A+Brazilian+Journal+of+Health+Economics+%2F+Jornal+Brasileiro+de+Economia+da+Saúde%22">JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde</searchLink>. Aug2020, Vol. 12 Issue 2, p109-120. 12p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22ECONOMIC+aspects+of+diseases%22">ECONOMIC aspects of diseases</searchLink><br /><searchLink fieldCode="DE" term="%22OPEN-angle+glaucoma%22">OPEN-angle glaucoma</searchLink><br /><searchLink fieldCode="DE" term="%22CATARACT+surgery%22">CATARACT surgery</searchLink><br /><searchLink fieldCode="DE" term="%22EYE+drops%22">EYE drops</searchLink><br /><searchLink fieldCode="DE" term="%22BRAZILIANS%22">BRAZILIANS</searchLink> – Name: SubjectGeographic Label: Geographic Terms Group: Su Data: <searchLink fieldCode="DE" term="%22BRAZIL%22">BRAZIL</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Objective: To evaluate whether the incorporation of the iStent® Trabecular Micro-Bypass implant is cost-effective for the treatment of primary open-angle glaucoma (POAG) in patients undergoing cataract surgery from the perspective of the supplementary healthcare system in Brazil. Methods: An analytical Markov model was developed and costs were obtained from the Brazilian supplementary health perspective (direct medical costs). Effectiveness was measured in "progression free life years (PFLY)". The time horizon was the average life expectancy of the Brazilian population. Data were obtained through review and critical analysis of the literature. The base case was: glaucomatous patients with cataract who underwent isolated cataract surgery and continued use of antiglaucomatous eye drops. We tested whether incorporating iStent® Trabecular Micro-Bypass in this scenario would be cost effective. The outcome measure was the incremental cost-effectiveness ratio (ICER: R$/PFLY). We performed univariate and probabilistic sensitivity analyses to test the robustness of the model. Results: Incorporating the iStent® Trabecular Micro-Bypass increases initial costs but improves disease control, making glaucoma stable longer and reducing future costs due to disease progression. The ICER was R$ 5,491.99/PFLY. The model was robust in sensitivity analyses. Conclusion: This analysis suggests that the incorporation of the iStent® Trabecular Micro-Bypass combined with cataract surgery would be cost-effective for joint cataract and POAG treatment in the supplementary health setting in Brazil. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Portuguese) Group: Ab Data: Objetivo: Avaliar se a incorporação do implante trabecular iStent® Trabecular Micro-Bypass é custo- -efetiva para o tratamento do glaucoma primário de ângulo aberto (GPAA) em pacientes que serão submetidos a cirurgia de catarata sob a perspectiva do Sistema de Saúde Suplementar no Brasil. Métodos: Foi elaborado um modelo analítico de Markov, cujos custos foram obtidos a partir da perspectiva da saúde suplementar brasileira (custos médicos diretos). A efetividade foi medida em "anos de vida livres de progressão (PFLY)". O horizonte temporal foi a expectativa de vida média da população brasileira. Os dados foram obtidos por meio da revisão e da análise crítica da literatura. O caso base foi: portadores de GPAA e catarata submetidos a cirurgia de catarata isolada e manutenção do uso de colírios antiglaucomatosos. Testou-se se a incorporação do iStent® Trabecular Micro- Bypass nesse cenário seria custo-efetiva. A medida de desfecho foi a razão de custo-efetividade incremental (RCEI: R$/PFLY). Realizou-se análise de sensibilidade univariada e probabilística para testar a robustez do modelo. Resultados: A incorporação do iStent® Trabecular Micro-Bypass gera um aumento dos custos inicialmente, mas melhora o controle da doença, tornando o glaucoma estável por mais tempo e diminuindo os custos futuros relacionados à progressão da doença. A RCEI foi de R$ 5.491,99/PFLY. O modelo mostrou-se robusto nas análises de sensibilidade. Conclusão: Esta análise sugere que a incorporação do implante iStent® Trabecular Micro-Bypass combinado com a cirurgia de catarata seria custo-efetiva para o tratamento conjunto da catarata e do GPAA no cenário da saúde suplementar no Brasil. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde is the property of JBES: Brazilian Journal of Health Economics and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=145621031 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.21115/JBES.v12.n2.p109-20 Languages: – Code: por Text: Portuguese PhysicalDescription: Pagination: PageCount: 12 StartPage: 109 Subjects: – SubjectFull: ECONOMIC aspects of diseases Type: general – SubjectFull: OPEN-angle glaucoma Type: general – SubjectFull: CATARACT surgery Type: general – SubjectFull: EYE drops Type: general – SubjectFull: BRAZILIANS Type: general – SubjectFull: BRAZIL Type: general Titles: – TitleFull: Custo-efetividade do uso do dispositivo de by-pass trabecular (iStent® Trabecular Micro- Bypass) associado a cirurgia de catarata para o tratamento conjunto do glaucoma primário de ângulo aberto e da catarata sob a perspectiva do Sistema de Saúde Suplementar no Brasil. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Paletta Guedes, Ricardo Augusto – PersonEntity: Name: NameFull: Pepe, Camila – PersonEntity: Name: NameFull: Teich, Vanessa – PersonEntity: Name: NameFull: Marcelo Gravina, Daniela – PersonEntity: Name: NameFull: Paletta Guedes, Vanessa Maria – PersonEntity: Name: NameFull: Chaoubah, Alfredo IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: Aug2020 Type: published Y: 2020 Identifiers: – Type: issn-print Value: 21752095 Numbering: – Type: volume Value: 12 – Type: issue Value: 2 Titles: – TitleFull: JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde Type: main |
| ResultId | 1 |
